Bardoxolone Methyl Improved Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease and IgA Nephropathy in the Ongoing Phase 2 Phoenix Study

Bardoxolone Methyl Improved Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease and IgA Nephropathy in the Ongoing Phase 2 Phoenix Study

May 25, 2018 Interim Data Demonstrate Significant Improvement in Kidney Function in Both Diseases Conference Call With Management Scheduled Today, May 25, 2018 at 8:00am ET IRVING, Texas, May 25, 2018 (GLOBE NEWSWIRE) — Reata Pharmaceuticals, Inc. (NASDAQ:RETA), a clinical-stage biopharmaceutical company, today announced that positive interim